

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

Admission of the ICS Elpis™ Bioresorbable Peripheral Balloon-Expandable Covered Scaffold System into Special Examination and Approval Procedure for Innovative Medical Devices

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that on 19 October 2026, the Company obtained formal written notice from the National Medical Products Administration (“**NMPA**”) confirming that the ICS Elpis™ Bioresorbable Peripheral Balloon-Expandable Covered Scaffold System (“**ICS Elpis™**” or the “**Product**”), independently developed by the Company’s subsidiary Biotyx Medical (Shenzhen) Co., Ltd. (“**Biotyx Medical**”), has been admitted into the NMPA Special Examination and Approval Procedure for Innovative Medical Devices (the “**Procedure**”). The Product is indicated for the treatment of atherosclerotic stenosis or occlusion of the common iliac artery and external iliac artery. It is the 20th product of the Company having obtained admission to the Procedure.

Peripheral arterial disease (PAD) is a common disease affecting the limbs of middle-aged and elderly people. Atherosclerotic stenosis or occlusion of the common iliac artery and external iliac artery represents a severe inflow lesion in lower-extremity PAD. Lesions at this site directly cause lower limb ischemia, and may lead to intermittent claudication, rest pain, and other symptoms, seriously affecting patients’ quality of life. For complex lesions complicated by calcified plaques, elastic recoil, and thrombosis, although conventional permanent metallic

stents can restore luminal patency, long-term foreign-body retention may give rise to problems such as late thrombosis, restenosis, and imaging artifacts. There is an urgent clinical need for an innovative solution that achieves both immediate vascular patency and long-term vascular remodeling.

ICS Elpis™ uses a high-strength iron-nitrogen alloy (Fe-0.05% N) as its scaffold backbone, covered with a high-porosity polycaprolactone (PCL) electrospinning fiber membrane. Compared with the permanent metallic stents commonly used in current clinical practice, ICS Elpis™ has stronger radial support and faster endothelialization rate, thereby effectively addressing complex lesions such as calcified plaques, elastic recoil, and thrombosis. After implantation, both the scaffold backbone and the fiber membrane can gradually degrade and be absorbed. After degradation is complete, the diseased vessel is expected to complete self-remodeling and restore a structure close to its natural physiological state, thereby eliminating the long-term safety and efficacy concerns potentially associated with permanent metallic stents implantation, reducing the long-term risk of thrombosis, and avoiding restenosis and repeated interventional procedures caused by persistent foreign-body irritation. In addition, once the scaffold has fully degraded, it will not produce artifact interference on subsequent imaging examinations, greatly improving the convenience of follow-up. ICS Elpis™ overcomes the limitations of traditional treatment, delivers significant clinical benefits, and greatly improves patients' quality of life.

ICS Elpis™ has completed all enrollment for the first-in-man (FIM) clinical trial. The study results demonstrated that both the device success rate and the procedural success rate reached 100%, and the vessels remained patent during the postoperative and follow-up periods, preliminarily confirming the safety and efficacy of the Product.

The Group possesses independent intellectual property rights to the Product. Currently, the Product has obtained clinical trial approval from the NMPA and is about to commence a randomized controlled clinical trial. With the steady progress of subsequent clinical trials, there will be more high-quality evidence-based medicine (EBM) evidence to further confirm the safety and efficacy of the Product.

The Board believes that the admission of the Product into the Procedure represents authoritative recognition of the innovative technology and clinical value of the Company's iron-based bioresorbable vascular scaffold series, and will accelerate its availability for patients in China. It also marks a new expansion of the Company's iron-based bioresorbable material platform in the field of peripheral vascular intervention, and will lay a solid foundation for the development of products for other indications on the iron-based bioresorbable material platform.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 20 October 2026

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Ms. WU Liping and Mr. FANG Yu being executive Directors; and Mr. ZHOU Luming, Ms. CHEN Dongxia and Mr. JIANG Feng being independent non-executive Directors.